TY - JOUR
T1 - Update on optimal management for pancreatic cancer
T2 - expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty
AU - Nguyen, Mike
AU - Segelov, Eva
AU - Goldstein, David
AU - Pavlakis, Nick
AU - Shapiro, Jeremy
AU - Price, Timothy J.
AU - Nagrial, Adnan
AU - Chantrill, Lorraine
AU - Leong, Trevor
AU - Chen, John
AU - Burge, Matt
AU - Karapetis, Christos S.
AU - Chau, Ian
AU - Lordick, Florian
AU - Renouf, Daniel
AU - Tebbutt, Niall
AU - Roy, Amitesh C.
PY - 2022
Y1 - 2022
N2 - Introduction: Pancreatic cancer remains a challenging malignancy due to the high proportion of patients diagnosed at advanced stages and the limited treatment options. This article discusses recent evidence in the management of both localized and advanced pancreatic cancer and offers an expert opinion on current best practice. Areas covered: For patients with localized disease, the evidence for adjuvant chemotherapy is discussed as well as emerging neoadjuvant approaches for resectable, borderline resectable, and locally advanced disease. Advances in metastatic disease are discussed including cytotoxic chemotherapy, targeted therapies, and the role of genomic testing to identify patients with molecular alterations. Reviewed literature included journal publications, abstracts presented at major international oncology meetings, and ongoing clinical trials databases. Expert opinion: Pancreatic cancer is a devastating diagnosis and despite recent advances has a very poor prognosis. Only a minority of patients, 20%, are diagnosed with potentially curable disease. The shifting paradigm toward neoadjuvant therapy may improve resectability and survival rates; however, robust evidence is required. Thus far, there has only been limited progress in advanced stage disease. Genomic testing may potentially identify more treatment targets although limited to small subgroups.
AB - Introduction: Pancreatic cancer remains a challenging malignancy due to the high proportion of patients diagnosed at advanced stages and the limited treatment options. This article discusses recent evidence in the management of both localized and advanced pancreatic cancer and offers an expert opinion on current best practice. Areas covered: For patients with localized disease, the evidence for adjuvant chemotherapy is discussed as well as emerging neoadjuvant approaches for resectable, borderline resectable, and locally advanced disease. Advances in metastatic disease are discussed including cytotoxic chemotherapy, targeted therapies, and the role of genomic testing to identify patients with molecular alterations. Reviewed literature included journal publications, abstracts presented at major international oncology meetings, and ongoing clinical trials databases. Expert opinion: Pancreatic cancer is a devastating diagnosis and despite recent advances has a very poor prognosis. Only a minority of patients, 20%, are diagnosed with potentially curable disease. The shifting paradigm toward neoadjuvant therapy may improve resectability and survival rates; however, robust evidence is required. Thus far, there has only been limited progress in advanced stage disease. Genomic testing may potentially identify more treatment targets although limited to small subgroups.
KW - adjuvant
KW - neoadjuvant
KW - Pancreatic cancer
KW - review
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85119672233&partnerID=8YFLogxK
U2 - 10.1080/14737140.2022.2002689
DO - 10.1080/14737140.2022.2002689
M3 - Review article
C2 - 34739362
AN - SCOPUS:85119672233
SN - 1473-7140
VL - 22
SP - 39
EP - 51
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
IS - 1
ER -